M&A in immuno-oncology heating up
Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion (170% premium)
Proprietary immuno-oncology (IO) platform synergistic with Sanofi’s existing therapeutic platforms
Lead asset THOR-707 (“not-alpha” IL-2) being explored across multiple solid tumor types alone and in combination with immune checkpoint inhibitors and other future IO combinations
Pre-clinical pipeline for oncology and autoimmune disorders
And of course if you look at the Synthorx chart lately, no one knew in advance, lol...